By using foundation models to analyze vast datasets, companies can create a synthetic 'standard of care' arm for single-arm Phase 1 trials. The AI matches patients based on deep clinical and genomic parameters, providing insights comparable to a much larger Phase 3 trial.

Beyond early discovery, LLMs deliver significant value in clinical trials. They accelerate timelines by automating months of post-trial documentation work. More strategically, they can improve trial success rates by analyzing genomic data to identify patient populations with a higher likelihood of responding to a treatment.

Unlike image recognition or NLP, clinical trial data possesses a unique and complex mathematical geometry. According to Dr. Juraji, this means generic AI models are insufficient. Solving trial failures requires specialized AI built to navigate this specific, difficult data landscape.

The industry's standard practice of selecting sites based on pre-existing relationships and convenience—the "easy button"—is a primary driver of failure. This leads to 80% of activated sites missing enrollment targets and 30% enrolling zero patients, a massive, systemic inefficiency that data-driven approaches can solve.

Instead of the high-risk approach of replacing a trial's control arm with digital twins, Unlearn.ai adds counterfactual data to every participant. This method increases a trial's statistical power, allowing for smaller control arms or a higher chance of success, while satisfying regulatory constraints for pivotal trials.

While most focus on AI for drug discovery, Recursion is building an AI stack for clinical development, where 70% of costs lie. By using real-world data to pinpoint patient locations and causal AI to predict responders, they are improving trial enrollment rates by 1.5x. This demonstrates a holistic, end-to-end AI strategy that addresses bottlenecks across the entire value chain, not just the initial stages.

Most tech vendors offer data only on sites within their proprietary network. Right.AI upended this by creating a digital twin for every research site globally, regardless of affiliation. This provides a comprehensive, unbiased view of the entire landscape, eliminating the limitations and blind spots of closed ecosystems.

Initially adopted for clinician retention, AI tools are now proving hard financial ROI. By unlocking new operating margin, AI allows health systems to reinvest in talent and technology. This creates a compounding flywheel that separates top organizations from those at risk of consolidation.

The AI platform discovers patterns in patient movement that expert clinicians felt were significant but couldn't objectively measure. This process of data-driven confirmation helps build trust and accelerates the adoption of AI tools by providing evidence for long-held clinical instincts, turning a subjective feeling into objective proof.